مورد إلكتروني
High measures of pre-chemoradiotherapy platelet-to-albumin ratio indicates poor prognosis in locally advanced pancreatic cancer patients
| العنوان: | High measures of pre-chemoradiotherapy platelet-to-albumin ratio indicates poor prognosis in locally advanced pancreatic cancer patients |
|---|---|
| المصدر: | Therapeutics and Clinical Risk Management |
| بيانات النشر: | Dove Medical Press International 2022 |
| تفاصيل مُضافة: | Selek, Uğur (ORCID 0000-0001-8087-3140 & YÖK ID 27211) Küçük, A.; Topkan, E.; Haksöyler, V.; Mertsoylu, H.; Besen, A.A.; Pehlivan, B. School of Medicine |
| نوع الوثيقة: | Electronic Resource |
| مستخلص: | Purpose: in a lack of similar research, we meant to retrospectively investigate the prognostic significance of pre-chemoradiotherapy (C-CRT) platelet-to-albumin ratio (PAR) on the survival results of locally advanced unresectable pancreatic adenocarcinoma (LAPC) patients. Patients and methods: the present analysis included 139 LAPC patients who received C-CRT in total. The utility of pre-C-CRT cutoff(s) reshaping survival data was explored using receiver operating characteristic (ROC) curve analysis. The primary and secondary objectives were the associations between PAR levels and overall survival (OS) and progression-free survival (PFS) outcomes. Results: at a median follow-up of 15.7 months (95% CI: 11.6-19.8), the overall cohort's median and 5-year OS rates were 14.4 months (95% CI: 11.8-17) and 14.7%, respectively, while the corresponding PFS rates were 7.8 months (95% CI: 6.5-9.1) and 11.2%. Because the ROC curve analysis found 4.9 as the optimal PAR cutoff for both OS and PFS [area under the curve (AUC): 75.4%; sensitivity: 72.4%; specificity: 70.3%], we divided the patients into two PAR cohorts: PAR<4.9 (N=60) and PAR>4.9 (N=79). Comparative analysis per PAR group exhibited significantly worse OS (11.2 vs 18.6 months, and 9.8% vs 20.9% at 5 years, P=0.003) and DFS (7 vs 14.3 months, and 7.6% vs 16.2% at 5 years, P=0.001) with PAR>4.9 versus PAR<4.9, respectively. In multivariate analysis, the N0 nodal status, CA 19-9 <= 90 U/mL, and PAR<4.9 were found to be independent predictors of improved OS and PFS. Conclusion: the pre-C-CRT high PAR (>4.9) robustly and independently prognosticated significantly worse OS and PFS results in inoperable LAPC patients who underwent definitive C-CRT. NA |
| مصطلحات الفهرس: | Health care sciences and services, Concurrent chemoradiotherapy; Pancreas cancer; Platelet-to-albumin ratio; Prognosis; Survival outcomes, Journal article, text/academic publication |
| URL: | Publisher version Koç University Institutional Repository |
| الإتاحة: | Open access content. Open access content |
| ملاحظة: | pdf English |
| أرقام أخرى: | T9K oai:libdigitalcollections.ku.edu.tr:IR/10509 1178-203X Kucuk, Ahmet, Erkan Topkan, Ugur Selek, Veysel Haksoyler, Huseyin Mertsoylu, Ali Ayberk Besen, and Berrin Pehlivan. ""Significance of Pre-chemoradiotherapy Platelet-to-albumin Ra: TCRM."" Therapeutics and Clinical Risk Management. (2022). IR03651.pdf WoS; Scopus; PubMed NA NA 1360597550 |
| المصدر المساهم: | KOC UNIV LIBR From OAIster®, provided by the OCLC Cooperative. |
| رقم الانضمام: | edsoai.on1360597550 |
| قاعدة البيانات: | OAIster |
| الوصف غير متاح. |